AUAUniversity Podcast Series: Episode No. 22

Clinical Investigations in the Treatment of Urothelial Carcinoma

Co-Host: Yair Lotan, MD

At the conclusion of these activities, participants will be able to:
1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs.
2. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

This educational series is supported by independent educational grants from:
Bristol-Myers Squibb
Genomic Health
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma